Teva Recalls Two Lots of Matzim LA for Failed Dissolution Specifications
Teva has recalled two lots of its Matzim LA (diltiazem hydrochloride) blood pressure treatment because they failed to meet dissolution specifications.
The recall is categorized as Class 2 category, meaning that the use of the product may cause temporary or medically reversible adverse health consequences, with a remote probability of serious adverse health consequences.
The affected lots include 8,022 bottles of 180 mg, 30-count items, and 5,677 bottles of 240 mg, 30-count products. Both lots have an expiration date of September 2022.
No reports of adverse events have been reported, the company said.